Abstract

CRC and IBD have been linked to the volatolome, which is a mixture of volatile organic
compounds (VOCs). The volatolome seems to have promise as a non-invasive biomarker
for the identification of CRC and IBD. Multiple researches have been conducted on the
volatolome's potential, utilising either chemical analysis or pattern-recognition approaches
to determine its potential. The existing literature on the potential of the volatolome as a
cancer and inflammatory bowel disease (IBD) biomarker was examined. The survey
examines 23 journal papers that were obtained electronically through major scientific
databases such as PubMed, Google Scholar, Scopus, IEEE, and Science Direct, which
were searched using sets of keywords. The papers were obtained through major scientific
databases such as PubMed, Google Scholar, Scopus, IEEE, and Science Direct, which
were searched using sets of keywords. Publication of the articles was made possible by the
use of major scientific databases such as Pubmed and Google Scholar, as well as the IEEE
and Science Direct. VOC analyses appear promising for future screening of CRC and IBD,
with potentially improved test performances allowing for earlier detection of IBD and CRC
and consequently earlier initiation of treatment, potentially reducing morbidity and
mortality rates as well as lower rates of (unnecessary) colonoscopies, according to the
studies included.